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Abstract
Background: Elucidation of the repertoire of secreted and cell surface proteins of tumor cells is relevant to molecular
diagnostics, tumor imaging and targeted therapies. We have characterized the cell surface proteome and the proteins
released into the extra-cellular milieu of three ovarian cancer cell lines, CaOV3, OVCAR3 and ES2 and of ovarian tumor cells
enriched from ascites fluid.
Methodology and Findings: To differentiate proteins released into the media from protein constituents of media utilized
for culture, cells were grown in the presence of [
13C]-labeled lysine. A biotinylation-based approach was used to capture cell
surface associated proteins. Our general experimental strategy consisted of fractionation of proteins from individual
compartments followed by proteolytic digestion and LC-MS/MS analysis. In total, some 6,400 proteins were identified with
high confidence across all specimens and fractions.
Conclusions and Significance: Protein profiles of the cell lines had substantial similarity to the profiles of human ovarian
cancer cells from ascites fluid and included protein markers known to be associated with ovarian cancer. Proteomic analysis
indicated extensive shedding from extra-cellular domains of proteins expressed on the cell surface, and remarkably high
secretion rates for some proteins (nanograms per million cells per hour). Cell surface and secreted proteins identified by in-
depth proteomic profiling of ovarian cancer cells may provide new targets for diagnosis and therapy.
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Introduction
Ovarian cancer is one of the most aggressive and lethal
epithelial cancers in women [1]. There are four major histological
types of epithelial ovarian cancer: serous, endometrioid, clear cell,
and mucinous, which differ in both their clinical behavior and
molecular characteristics. The serous subtype is the most
commonly diagnosed and is responsible for most ovarian cancer
deaths [1]. Currently there is no accurate non-invasive diagnostic
test for ovarian cancer; most patients are diagnosed at an
advanced stage [2], presenting with metastases and invasion of
the peritoneal cavity and ascites [3]. Therefore, the identification
of proteins that are abundantly and predominantly expressed in
ovarian cancer presents a valuable undertaking and may provide
early clues to the presence of ovarian cancer, and/or indications of
a molecular subtype that could help to guide treatment.
Identification of the repertoire of proteins that are cleaved from
the cell surface and of proteins that are otherwise released into the
extracellular compartment can contribute to our understanding of
tumor behavior, to the identification of potential diagnostic
markers detectable in circulation and of potential imaging and
therapeutic targets that remain displayed on the cell surface.
During the metastasis of ovarian cancer, the production of matrix-
degrading proteinases by tumor cells contributes to the disruption
of cell interactions through a mechanism of shedding of adhesion
molecules. These mechanisms have been demonstrated in ovarian
cancer context for ALCAM [4] and for epithelial cadherin
(CDH1)[5].
In-depth, quantitative proteomics allows this delineation of
proteins expressed in tumor cells and in sub-cellular compartments
[6]. Several proteomic studies have analyzed ovarian tumor tissue
[7,8], cell lines [9–11], ascites fluid [12] and blood from patients
with ovarian cancer [13,14]. However, there is still a need to
systematically characterize and compare sets of proteins whose
locations make them especially relevant to diagnosis and
treatment, notably proteins at the cell surface or those released
into the extra-cellular milieu, and to determine the mechanism
and dynamics of protein release into the extracellular space.
We characterized three ovarian adenocarcinoma cell lines,
OVCAR3, CaOV3 and ES2, as well as ovarian cancer cells
PLoS ONE | www.plosone.org 1 June 2008 | Volume 3 | Issue 6 | e2425enriched from ascites fluid with an in-depth proteomic analysis of
whole cell lysates, the cell surface proteome and proteins released
into the extra-cellularcompartment. Detailedexploration of thedata
revealed several interesting biological phenomena, including exten-
sive shedding of extra-cellular domains for proteins expressed on the
cell surface and high secretion rates of a subset of proteins. The data
also includes a number of protein markers known to be associated
with ovarian cancer. The resulting public dataset is a resource for
discovery of diagnostic and therapeutic targets and a rich source of
information regarding the distribution of proteins between the cell
interior, the cell surface and the extracellular space.
Methods
Culture and isotopic labeling of ovarian cancer cells
OVCAR3, CaOV3 and ES2 cells were grown in DMEM media
(Invitrogen) containing 0.1% of dialyzed fetal bovine serum (FBS)
(Invitrogen) and
13C-lysine instead of regular lysine, for 7 passages
(1:2) according the standard SILAC protocol [15]. Incorporation
of
13C Lys isotope exceeded 90% of the total protein lysine
content. The same batch of cells was used for extracting cell
surface proteins and for analysis of conditioned media and whole
cell lysate proteins. The secreted proteins were obtained directly
from the cell conditioned media after 48 h of culture. Cells and
debris were removed by centrifugation at 50006g and filtration
through a 0.22 mm filter. Total extracts of cells were obtained by
sonication of ,2610
7 cells in 1 ml of PBS containing the
detergent octyl-glucoside (OG) (1% w/v) and protease inhibitors
(complete protease inhibitor cocktail, Roche Diagnostics, Ger-
many) followed by centrifugation at 20,0006g.
Tumor cells were obtained from 2.2 l of ascites fluid from one
patient with ovarian serous adenocarcinoma. Ascites samples were
collected under an IRB approved protocol. After centrifugation at
2000 rpm for 5 min, the pellet of cells was washed 3 times with PBS
followed by centrifugation at 2000 rpm for 10 min. A gradient of
percoll (30 to 60%) was used to enrich the preparation in cells
derived from tumors and eliminate contaminant mononuclear blood
cells. Tumor cells comprised ,80% of viable cells in the resulting
sample, as evaluated by microscopic inspection. The ascites cell
conditioned media was obtained after 24 h of culture in 0.1% of
bovine serum albumin (BSA), without addition of fetal bovine serum
(FBS). Cells and debris were removed by centrifugation at 50006g
and filtration through a 0.22 mmf i l t e r .
Capture of cell surface proteins
To isolate cell surface proteins from the three adherent ovarian
cancer cell lines, ,2610
8 cells were biotinylated in the culture
plate after extensive PBS rinsing, with 10 ml of 0.25 mg/ml of
Sulfo-NHS-SS-BIOTIN in PBS at room temperature (23–24uC)
for 10 min. The residual biotinylation reagent was quenched with
10mM Lysine. Enriched tumor cells from ascites were washed
three times in PBS and biotinylated in suspension (2.5610
8cells/
ml) with 0.48mg/ml of Sulfo-NHS-SS-BIOTIN in PBS for 30 min
at room temperature (23–24uC). The residual biotinylation
reagent was quenched with 10mM Lysine in both cell line and
ascites preparation. Protein extraction was performed in a solution
containing NP 40 detergent 2% (v/v) with cell disruption by
sonication followed by centrifugation at 20,0006g. Biotinylated
proteins were chromatographically isolated by affinity chroma-
tography using 1 ml of UltraLink Immobilized Neutravidin
(Pierce) according to manufacturer instruction. Proteins bound
to the column were recovered by reduction of the biotinylation
reagent with 5 ml of a solution containing 65 mmol of DTT and
1% octyl-glucoside (OG) detergent for 1 h at 37uC. Eluted
proteins were subsequently alkylated with 200 mmol of iodoace-
tamide at room temperature.
Fractionation of cell extracts
Cell surface, conditioned media and total extract were
fractionated by reversed-phase chromatography, using respectively
500 mg, 1 mg and 1 mg of total protein. All the cell extracts were
reduced and alkylated with iodoacetamide prior to chromatogra-
phy. Separation was performed in a POROS R1/10 column
(Applied Biosystems–4.6650 mm) at 2.7 ml/min using a linear
gradient of 10 to 80% of organic solvent over 30 minutes run.
Solvent system used was: aqueous solvent–5% acentonitrile/95%
water/0.1% of trifluoracetic acid; organic solvent-75% acetoni-
trile/15% isopropanol/10% water/0.095% trifluoracetic acid.
Fractions were collected at a rate of 3 fractions/minute.
Protein identification by LC-MS/MS
Protein digestion and identification by LC-MS/MS was
performed as described previously [16]. Briefly, each one of the
reversed-phase fractions was individually digested in-solution
digestion with trypsin (400 ng/fraction), and grouped into 15 to
21 pools for each cell line and each compartment (i.e. cell surface,
conditioned media and soluble whole cell lysate) based on
chromatographic features. Pools were individually analyzed by
LC-MS/MS in a LTQ-ORBITRAP mass spectrometer (Thermo-
Finnigan) coupled to a nanoflow chromatography system (Eksi-
gent) using a 25 cm column (Picofrit 75 mm ID, New Objectives,
packed in-house with MagicC18 resin) over a 90 minute linear
gradient. Acquired data was automatically processed by the
Computational Proteomics Analysis System–CPAS [17]. The
tandem mass spectra were searched against version 3.13 of the
human IPI database. A fixed modification of 6.020129 mass units
was added to lysine residues for database searching to account for
incorporation of the heavy lysine isotope. To estimate the
significance of peptide and protein matches, we applied the tools
PeptideProphet [18] and ProteinProphet [19]. Identifications with
a PeptideProphet probability greater than 0.75 were selected and
submitted to ProteinProphet. The latter infers a minimal set of
proteins that explain the peptide evidence, assigning a probability
to each protein based on the combined peptide probabilities. The
derived protein identifications were filtered at a 1% error rate
based on the probability that the best match obtained would fall in
the distribution of random database matches [20]. The spectral
counting method [21] was used to estimate protein enrichment for
each compartment. The total number of spectral counts for each
protein group output by ProteinProphet was used for the semi-
quantitative analysis. Each dataset was normalized by the total
number of counts in the entire experiment. The enrichment factor
was calculated by the following expression: [(Cxp /Nf)+1]/(Cte
p+1), where Cx represents counts of each protein (p) in the sub-
proteome (secretion or cell surface); Nf is the normalization factor
(presented in the top of Table S1); Cte is the counts for the same
protein (p) observed in the total extract of the respective cell. The
addition of 1 to the counts was intended to take into account those
proteins for which no observation was made in one of the sub-
proteomes and represents the minimum enrichment factor for that
particular protein.
Results
Proteomic Analysis of Ovarian Cancer Cells
A comprehensive proteomic profile of the OVCAR3, CaOV3
and ES2 cell lines, and ovarian cancer cells from ascites of a
patient with serous ovarian cancer was performed. The general
Ovarian Cancer Cells Proteome
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followed by mass spectrometric data acquisition by LC-MS/MS
and data analysis, as described in Figure 1. Overall, we performed
215 LC-MS/MS runs, which correspond to more than two million
MS scans.
Total cell lysates. A reversed-phase chromatogram
representing the fractionation of intact proteins in the whole cell
lysate of ES2 cells is presented in Figure 2. Overall, the analysis
yielded some 3,000 high confidence protein identifications for each
cell population analyzed (Figure 3). The number of protein
identifications from total cell extracts in common between the
three cell lines was 1179, and ranged from 2011 to 2267 for two
cell lines (Figure 3A). On average, 655 proteins were uniquely
identified in one cell line. In addition to biological heterogeneity,
part of the variability in identified proteins between cell lines could
be attributed to mass spectrometric undersampling of low
abundance proteins.
Cell surface proteins. We relied on a labeling strategy with
lipid impermeable biotin to tag and capture proteins exposed on
the cell surface of OVACAR3, CaOV3, ES2 cell lines and ascites
derived tumor cells (Figure 1). From approximately 2610
8 cells,
we obtained some 500 mg of biotinylated proteins, representing
,1–2% of the total cell protein mass. The list of protein
identifications is presented in Table S1.
Proteins released into the medium. The cell lines were
grown in culture media containing heavy isotopes of lysine.
Isotopic labeling of proteins was intended to discriminate between
proteins released from growing cells and proteins intrinsic to
supplemented media. After 48 h of culture, the concentration of
proteins increased from 100 mg/ml to 225 mg/ml in the
conditioned medium of OVCAR3 cells. Because ,15% of
predicted human tryptic peptides with more than 6 amino acids
are identical between human proteins and their bovine
counterparts, isotopic labeling of cell proteins provided a means
to differentiate human proteins secreted by cultured cells from
bovine proteins present in the medium. For ascites derived cells,
the media were collected after 24 h of culture in the presence of
0.1% bovine serum albumin (BSA). Approximately 1 mg of
Figure 1. Experimental overview of the analysis of whole cell lysate, cell surface proteins and proteins from the conditioned media
of ovarian cell lines and tumor cells derived from ascites.
doi:10.1371/journal.pone.0002425.g001
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cells from ascites were fractionated using the same reversed-phase
chromatography method as used for whole cell lysates, and
individual fractions were analyzed by LC-MS/MS. For cultured
cell lines, proteins that were identified exclusively from peptides
without labeled lysine residues and that were identical in sequence
Figure 2. Reversed-phase fractionation of the total extract of ES2 cell line. The chromatogram shows the profile of fractionation of 1 mg of
whole cell lysate. We collected 18 fractions of this sample for further protein identification by LC-MS/MS. The decomplexing of samples prior LC-MS/
MS analysis by intact protein fractionation improves significantly the identification of low abundance proteins [16]. The boxes under the
chromatographic profile indicated the fractions analyzed. The solid dark line indicates the gradient used in the separation.
doi:10.1371/journal.pone.0002425.g002
Figure 3. Protein identifications in ovarian cancer cells. Venn diagrams show overlap between proteins identified in different cell populations
analyzed. A. Identifications from whole cell lysates of the three cell lines analyzed. B. Proteins identified in the three sub-proteomes (whole cell lysate,
conditioned media and cell surface). C. Proteins identified in tumor cells enriched from ascites exhibiting 80% concordance with proteins identified in
the three ovarian cancer cell lines. D. Number of proteins identified in each dataset. Table S1 lists the proteins identified in this study.
doi:10.1371/journal.pone.0002425.g003
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and were not included in the list of proteins released from cells.
The proteomic profile of ovarian cancer cells lead to the
identification of 6,462 proteins (Figure 3D). We used strict criteria
for protein identifications, considering only valid those proteins
with minimum ProteinProphet probability threshold of 0.9. For
this threshold, the estimated false identification rate is less than
1%. This dataset represents the most detailed and comprehensive
proteomic study of cell populations for ovarian cancer. The depth
of analysis and coverage achieved at the protein level in this study
is equivalent to the depth of analysis to uncover expressed genes at
the RNA level.
Protein distribution between the intracellular, cell surface
and extracellular compartments
A comparative analysis of proteins in different compartments
allows assessment of the extent of enrichment of proteins on the
cell surface and in the extracellular compartment. We relied on the
spectral counting method [21] to estimate protein enrichment for
each compartment. After normalization to the total number of
spectral counts, proteins with greater number of counts in a
compartment (cell surface or conditioned medium) compared to
total cell lysates were considered enriched in that compartment
(Figure 3). The corresponding enrichment factors observed for all
proteins identified is presented in Table S1.
Proteins attributed to the three cellular compartments were
analyzed with the Ingenuity Pathways Analysis (IngenuityH
Systems, www.ingenuity.com), and with algorithms for prediction
of transmembrane alpha-helix domains (TMHMM)[22] and for
the presence of signal peptides (SignalP)[23] (Figure 4A). This
analysis showed substantial concordance between demonstrated
location based on our proteomic profile and predictions from
database analysis. This concordance was particularly evident for
the top 10% enriched proteins when contrasted with the 10% least
enriched proteins (Figure 4B and 4C), supporting the strategy
utilized to analyze specific compartments. The significant number
of proteins annotated as nuclear or cytoplasmic and present
among the identifications in both the conditioned media and cell
surface sub-proteomes is noteworthy. To some extent, occurrence
of these predominantly intracellular proteins may be due to cell
lysis since around 1% of cells in culture were estimated to be dead
based on trypan blue staining. However, there is prior evidence for
the occurrence of cytoplasmic proteins bound to the extracellular
membrane, particularly in cancer [24,25].
Proteins secreted by the cells are expected to diffuse through
tissues and enter the circulation. Therefore, in contrast to
intracellular proteins, secreted proteins may be more likely
detectable in plasma. We compared ovarian cell protein profiles
by compartment with proteins listed in the Human Plasma Peptide
Atlas [26]. Of the total 6,462 proteins identified in this study,
2,341 (36%) occurred in the Human Plasma Peptide Atlas (Table
S1). The top 100 proteins that were enriched in conditioned media
for each of the cell populations analyzed were more highly
represented in the Peptide Atlas (65 to 78%) compared to the
overall 36% representation. These results suggest that secreted
proteins are more abundant in plasma that non-secreted proteins.
Similarities between cell lines and ascites tumor cells
The three cell lines in this study represent well characterized in
vitro models for ovarian cancer. OVCAR3 and CaOV3 are
derived from human serous ovarian adenocarcinoma [27,28] and
ES2 is derived from clear cell carcinoma [29]. Differences in
histology are paralleled by differences in protein profiles, as
reflected in the clustering analysis using the spectral counts as
measures of protein abundance (Figure S1). This is evident from
observations that the secreted and surface sub-proteomes of ES2
are significantly different from those of the two other cell lines
analyzed.
The tumor cells enriched from ascites we analyzed were derived
from a patient with serous ovarian adenocarcinoma. Eighty
percent of the proteins identified in the ascites tumor cells were
also identified in one or more of the cell lines (Figure 3C). As
indicated in Figure S1, patterns for the patient’s tumor cells
isolated from ascites have greater similarity with CaOV3 and
OVCAR3 than with ES2.
Another way to account for similarities can rely on observation
of proteins already known to be associated with the disease.
Several kallikreins have been previously associated with serous
ovarian adenocarcinoma [30]. KLK6, KLK7 and KLK 9 were
abundant in the conditioned medium from ascites derived tumor
cells, OVCAR3 and CaOV3, but not in ES2 cell conditioned
media (Table S2). These observations suggest again greater
similarities among the serous adeonocarcinoma cell lines OV-
CAR3 and CaOV3 and the tumor derived cells as well as the
differences in relation to clear cell derived ES2 cell line.
Some differences were observed between ascites derived cells
and cell lines. Some proteins were exclusively detected and
enriched on the surface or in culture media of ascites derived
tumor cells. These include proteins such as ABP1 (amiloride-
sensitive amine oxidase) and MMP7 (and matrix mettaloprotease
7), the transcripts for which are notably abundant in various sub-
types of ovarian cancer, and others encoded by mRNAs with high
expression levels in specific histological types of ovarian cancer
(Table S3). Of note is the fact that several of the proteins enriched
exclusively in tumor cells from ascites have very low tissue
expression in normal ovary [31] (Table S3). These proteins are
possibly derived from leukocytes and mesothelial cells that would
have been co-purified from ascites fluid.
Shedding of surface membrane proteins into the extra-
cellular compartment
In support of our experimental and analytic approach, we found
that a substantial proportion of proteins annotated as membrane
proteins were identified in culture medium, representing more
than 25% of all identified proteins as for example in OVCAR3
and ascites derived tumor cells (Figure 4a). Several of these
proteins were significantly enriched both on the cell surface and in
the culture medium (Table S4). Analysis of peptides identified
indicated that for the most part, these peptides were derived from
extracellular domains of cell surface proteins as shown in
Figure 5A, suggesting ectodomain shedding.
Epithelial cadherin (CDH1) clearly illustrates the shedding
process, since sequence coverage of the extracellular domain is
predominant in the secreted fraction, whereas peptide coverage
spanning both intra and extra cellular domains was observed for
the protein isolated from the cell surface fraction. We compared
the mass spectrometry based findings with western blot analysis of
ovarian cell line and ascites-derived tumor cells. Intact forms of
CDH1 were observed in whole cell lysates, together with lower
molecular fragments containing the intracellular domain. Howev-
er, in ascites cells there is a predominance of low molecular weight
fragments containing only the intracellular domain both in total
cell extract and cell surface, indicating that the shedding process is
more extensive in tumor cells than in cell lines. Forms of CDH1
containing the intracellular domain were not detected in the
conditioned media of these cells (Figure 5b). The process of
shedding of CDH1 has recently been described for ovarian cancer
cells [5], in support of our mass spectrometry based investigations.
Ovarian Cancer Cells Proteome
PLoS ONE | www.plosone.org 5 June 2008 | Volume 3 | Issue 6 | e2425Figure 4. Distribution by cellular location of proteins identified in ovarian cancer cells. A. The cellular localization classification used a
combination of annotations from Ingenuity Pathway Analysis software and computational prediction of transmembrane alpha-helix (TMHMM) and
signal peptides (SignalP). B. and C. Comparison of the top 10% enriched proteins in conditioned media or cell surface (B and C, respectively) with the
least enriched 10% demonstrating strong concordance between predicted cellular location and the specific sub-proteome analyzed.
doi:10.1371/journal.pone.0002425.g004
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the cadherin family of adhesion molecules in conditioned media,
such as neural cadherin (CDH2), calsyntenin-1 (CLSTN1),
alcadein beta (CLSTN3), desmoglein-1 (DSG1) and desmoglein-
2 (DSG2). Based on Ingenuity Pathway Analysis annotation, most
of these membrane proteins identified enriched in the conditioned
media are related to the processes of cell adhesion and cell
movement (Table S4). The process of cleavage and shedding is not
uniform for all proteins as we have observed a significant number
of proteins enriched in the cell surface fraction that are not
detected in the cell culture medium (Table S4).
Protein secretion rates
Analyzing proteins released into the medium by cultured cells is
an attractive strategy to identify potential circulating markers. The
potential for detection of increased levels of a protein in circulation is
dependent inpartonthe rateatwhichthe protein isreleased intothe
extracellular space and ultimately the blood compartment by the
tumor relative to other tissues. In the list of proteins most enriched in
culture media relative to whole cell lysates were two tissue
metalloprotease inhibitors (TIMP 1 and TIMP2) (Table S2). These
proteins have direct diagnostics potential in ovarian cancer [32].
We assessed the enrichment factor for TIMP1 by Western blot
analysis (Figure 6a). TIMP1 occurred predominantly in the
secreted compartment of all cell lines, consistent with predictions
based on spectral counting. We also performed a time-course
measurement of TIMP1 and TIMP2 concentration in the
conditioned medium to estimate the secretion rate of these
proteins for all three cell lines (Figure 6b). TIMP1 was shown to
have a low secretion rate in OVCAR3 cells relative to other cell
lines, which is consistent with our Western blot analysis. We
calculated the secretion rates of TIMP1 and TIMP2 to be on the
order of nanograms of protein per million cells, per hour. Based on
a secretion rate of 3 ng of TIMP1 per million cells per hour and
without taking into account the rate of degradation and clearance
in serum, it would take around 10
8–10
9 tumor cells and several
days of output to alter the levels of TIMP1 that occur in normal
human serum, which is 87–524 ng/ml.
Discussion
We present here an in-depth proteomic analysis of ovarian
cancer cell lines and ovarian cancer tumor cells, including separate
analyses of cell surface and secreted proteins. The study was based
on intact protein fractionation followed by trypsin and LC-MS/
MS [16,33], allowing sensitive detection of low abundance
proteins. Altogether, we generated an extensive profile of proteins
consisting of more than 6,500 unique identifications with an error
rate less than 1%. A recent study of ascites fluid consisting of
proteins derived from mixed populations of cells [12] identified
2,737 proteins. 2,307 (84%) of the proteins reported in that study
were encompassed among proteins identified in our study.
The use of spectral counts as a measure of abundance coupled
with comparisons of proteins found in the cell surface or
extracellular compartments and in whole cell lysate profiles,
allowed identification of proteins enriched in particular compart-
ments. Peptide counting provides abundance estimates that
correlate reasonably well with those determined by other methods
[34]. In our study we also observed a good correlation between
estimates of abundance of tissue inhibitor of metalloproteinase 1
(TIMP1) and epithelial cadherin (CDH1) based on spectral
counting and assessment based on Western blot analysis. Isotopic
labeling with SILAC [15] also provided an efficient means to
distinguish proteins in conditioned media that are released from
cultured cells from proteins contributed by bovine serum in the
culture medium.
Figure 5. Shedding of membrane proteins from ovarian cancer cells into conditioned media. A. Identification of peptides spanning
extracellular domains of transmembrane proteins detected in the conditioned media, consistent with a shedding process. CDH1 (epithelial cadherin)
illustrates well this process, since peptides spanning only the extracellular domain are observed in conditioned media while peptides spanning both
intracellular and extracellular regions were detected on the surface of Ovcar3 and ascites cells. Red traces indicate extracellular domains and blue
traces indicate intracellular domains. Transmembrane regions are indicated in the yellow boxes. Dark boxes indicate peptides identified. B. Western
blotting of CDH1 using a specific antibody against the intracellular domain (mouse anti-E-cadherin clone 36, #610181, BD Biosciences)
demonstrating cleavage of the full length CDH1. There were no peptides derived from the intracellular domain in conditioned media.
doi:10.1371/journal.pone.0002425.g005
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surface protein shedding and release to the protein composition of
the extra-cellular compartment. Proteins highly enriched in culture
media represent a potential source of circulating markers for ovarian
cancer. Transcripts corresponding to some of these proteins (e.g.,
KLK6,7and 9) arerelativelyabundantinovarian tumorscompared
to most normal tissues [35]. There is already evidence for the
occurrence of most of these proteins in normal human plasma. Of
the 60 proteins listed in Table S2, 48 (80%) were present in the
Human Plasma Peptide Atlas [26]. However, to be effectively
detected at increased levels and as expected of a biomarker
candidate, a protein should have high secretion rates specifically
by tumor cells, low concentration in normal plasma and also a low
clearance from the circulation. Proteins that we identified in the
conditioned medium (Table S2) whose corresponding mRNAs are
relatively highly expressed in ovarian cancer tissue include TIMP1,
IGFBP3 (insulin-like growth factor-binding protein 3), MDK
(midkine), PROS1 (vitamin k-dependent protein s) and SLPI
(secretory leukoprotease inhibitor). Several other proteins that have
been proposed as potential biomarkers for ovarian cancer were
identified in the extracellular compartment of cells analyzed in this
study, including WFDC2 (HE4) and MUC16 (mucin 16, CA125), a
membrane glycoprotein that was significantly enriched in condi-
tioned media from CaOV3, OVCAR3 and ascites cancer cells and
which is used as a marker of ovarian cancer [36]. These findings
suggest that other proteins enriched in the culture media and/or on
the cell surface may have potential as markers for ovarian cancer.
We observed a substantial enrichment of CDH1 both on the cell
surface and in culture media, likely as a result of a shedding
process driven by metalloproteases [5]. Shed extracellular domains
of proteins have potential utility as circulating biomarkers, as has
been suggested for some cadherins [37] . Other soluble fragments
of membrane proteins, which we found in the extracellular
compartment, notably MSLN (mesothelin) have also been
proposed as potential biomarkers [38].
The process of surface protein shedding as observed in ascites
derived tumor cells is relevant to tumor invasion and metastasis
[3], as exemplified by the role of cadherins. Members of this family
involved in adherent junctions and desmossomes include desmo-
gleins (DSG1 and DSG2) and the recently discovered family of
calystenins (CLSTN1 and CLSTN3). Interestingly, calystenins are
localized in the postsynaptic membrane and proteolytically
cleaved N-terminal fragments corresponding to the extracellular
domain have been observed. Proteolytic cleavage of the extracel-
lular domain of calystenins is known to impact directly Ca2+
signaling in brain [39].
The dynamics of shedding of cell surface proteins and release
into circulation (or conditioned media as detected here) has
relevance to diagnostics and imaging. However their reduced
representation on the cell surface and occurrence in circulation
diminishes their utility as imaging or therapeutic targets compared
to stable, non-shed proteins. For example, integrin alpha 6
(ITGA6) is significantly enriched on the cell surface of all three
ovarian cell lines as well as the ascites tumor cells, is relatively
Figure 6. Detection of TIMP 1 and TIMP 2 in the conditioned media of ovarian cancer cells. A. The Western blot shows the presence of
TIMP1 only in the conditioned media of all the 4 ovarian cancer cells. OVCAR3 expressed significantly less TIMP1 in comparison to the other cells.
Same mass of protein (5mg) was loaded in each lane of the gel for this analysis. std corresponds to recombinant TIMP1 used as a standard control; TE
corresponds to whole cell lysate; SE to conditioned medium; and SU to cell surface proteins. B. the secretion rate measurement of TIMP1 and TIMP2
used commercial ELISA kits (R&D systems). Conditioned media were diluted 1:15 and 1:60 for the analysis of TIMP1 and TIMP2, respectively. The
secretion rate was estimated based on the slope of the curve at linear time points.
doi:10.1371/journal.pone.0002425.g006
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conditioned media (see Table S4).
Our findings indicate that the serous ovarian cancer derived cell
lines OVCAR3 and CaOV3 are good models of serous ovarian
cancer to identify potential biomarkers given the similarities we
have observed with tumor cells isolated from ascites from a patient
with serous ovarian cancer. Our data also indicates extensive cell
surface protein shedding in tumor cells obtained from ascites. The
extensive proteomic profiling of key compartments for the four
ovarian cancer cell populations that we have studies provides a
rich dataset for further exploration and integration with other data
for identification of potential circulating markers and imaging and
therapeutic targets.
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